U.S. Treasury Considers New Screening Rules for Investments in Chinese Biotech

Treasury Department officials are reviewing possible measures to screen U.S. capital flowing into Chinese biotechnology firms, according to multiple sources familiar with the discussions.

The review could lead to new restrictions that limit or condition investments, though no specific policy details or timeline have been disclosed. The move reflects broader concerns about national security and supply chain dependencies.

If implemented, the rules could affect venture capital, private equity and public market investors with exposure to China biotech, potentially reshaping funding patterns and prompting companies to seek alternative financing routes.